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Photoaffinity Labelling (PL) is a powerful method in the chemical proteomic approach of protein 
functions [1-5]. This method is especially useful for the identification of ligand-binding sites of 
target proteins and for the investigation of ligand–receptor interactions. The use of affinity-labeled 
inhibitors to covalently modify the site of interaction and subsequent analysis of the protein have 
been very effective in providing useful informations about inhibitor binding for a multitude of 
therapeutic  target  proteins.  Therefore,  it  could  reasonably  be  applied  in  drug  discovery  and 
development processes.
For example, such approach can be used to obtain structural information detailing the association 
between the enzyme HIV-1 integrase (IN) and inhibitors under development. IN, the enzyme that 
mediates the insertion of viral DNA into the host genome, is an attractive and validated target for 
developing novel antiretroviral agents [6].  Application of PL to IN has elucidated a small number 
of inhibitor-binding sites to atomic resolution [7]. Recently, a class of compounds bearing a β-
diketo acid (DKA) moiety, independently discovered by scientists from Shionogi & Co. Ltd. and 
Merck Research Laboratories, have emerged as the most promising lead in anti-HIV-1 IN drug 
discovery  [8].In  this  context,  to  facilitate  identification  of  DKA-binding  sites,  a  series  of 
photoactivable compounds, related to two potent diketo acid inhibitors (L-731,988 I,  and S-1360 
II), were prepared as DKA photoaffinity probes. 
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The photoprobes were tested for their  ability to inhibit  IN catalytic  activity in in vitro assays 
employing purified enzyme.  All tested compounds showed anti-IN activity in low micromolar 
concentration range. In cross-linking assays  designed to measure disruption of substrate DNA 
binding, the photoprobes behaved similarly to a reference DKA inhibitor. Molecular modeling 
studies suggest that  such derivatives  interact  within the IN active site in similar  manner  with 
respect to the parent diketo acid compound. Analogues Ia-c represent novel photoaffinity ligands, 
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